Navigation Links
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/25/2008

ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury Future Leaders in the Biotech Industry Conference, to be held at the Millennium Broadway Hotel & Conference Center, March 27, 2008. Mr. Burns' presentation is scheduled for Thursday, March 27, 2008 at 4:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients, and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases,
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces 2008 Corporate and Clinical Program Priorities
2. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
3. EntreMed to Present at BIO CEO and Investor Conference
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. EntreMed Appoints Senior Vice President of Research and Development
7. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
8. Osteotech to Present at the Sidoti Conference in New York
9. BioMS Medical to present at BioCentury Conference
10. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, ... webcast of a presentation to investors on Tuesday, ... p.m. PDT.  The presentation will include an overview ... To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... of Engineering at the University of Delaware, is ... in energy engineering, environmental sustainability and electronics. , ... rock with a well-defined, crystalline structure. At the ... decided that zeolites can separate molecules with size ... (one-tenth of a nanometer), making them useful to ...
(Date:7/24/2014)... 24, 2014 SRI International has been awarded ... Institute of Allergy and Infectious Diseases (NIAID), part of ... of potential therapies for HIV infection and AIDS. The ... and AIDS and the complications and opportunistic infections associated ... sexual transmission of HIV. According to ...
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4University of Delaware researcher describes new approach for creating organic zeolites 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... German . The heat which occurs in ... even a problem. On the contrary: It could be used ... more efficiently! These are two of the several potential applications ... (PTB). This so-called "thermoelectric voltage" may well be very interesting ...
... Spherix Incorporated (NASDAQ: SPEX ) ... diabetes, metabolic syndrome and atherosclerosis, and providers of ... biotechnology and pharmaceutical companies -- today announced that ... dyslipidemia in new studies of apolipoprotein E-deficient mice ...
... Oct. 24, 2011 Reaction Biology Corporation ("RBC"), ... services in epigenetics, today announced the rollout of ... research. RBC,s initial offerings will emphasize the histone ... has been no previous commercial source. ...
Cached Biology Technology:Magnetic nanoswitch for thermoelectric voltages 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 3Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 4Reaction Biology Launches Recombinant Methyltransferase Line 2
(Date:7/25/2014)... scars on this false-color image from the Terra satellite show ... rash of wildfires in Eastern Russia. The burn scars ... background. The wildfires have broken across the remote parts ... this false-color image from the MODIS instrument, it is ... that continue. Two recent image features noted below show the ...
(Date:7/25/2014)... the International Journal of Cancer earlier this ... based on findings showing successful reduction in the risk ... of cells in the cervix. , The findings ... cells, or SCJ cells. These cells reside in the ... of cervical cancer. A research team co-led by Christopher ...
(Date:7/25/2014)... and Diabetes increasingly consume the healthcare community ... attention. , To address the worldwide ... low-and middle-income countries, global leaders in diabetes, ... in diabetes prevention and development of diverse ... text. , This book on "Global ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... highways or drive down any city street this ... manicured beds of flowers maintained by community volunteers ... gardens are taking root. Aside from the ... including landscaping and gardens, can help drivers reduce ...
... University doctoral student Jennifer Smith has shed new light on ... hunt for their food alone. In a paper ... a student in MSU,s Department of Zoology, shows that while ... cooperative societies, they also realize that venturing on their own ...
... 28, 2008The 2008 American Society for Microbiology (ASM) ... being presented to Stephen C. Edberg, Professor, Department ... School of Medicine, and Director, Clinical Microbiology Laboratory, ... this award recognizes a distinguished scientist for research ...
Cached Biology News:New roadside beautification concept studied 2Spotted hyenas can increase survival rates by hunting alone 2American Society for Microbiology honors Stephen C. Edberg 2
... ESGRO Complete Derivation Kit is intended ... cells from delayed blastocysts in serum-free ... Clonal Grade ... Blastocyst Incubation Medium Trypsin Solution ...
AedestaTM Animal Organ/Tissue Perfusion Soln....
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: